NCT03238534 - Efficacy and Safety Evaluation of Neobianacid® in GERD and EPS | Biotech Hunter

Enrollment

275

Participants

Timeline

Start Date

September 12, 2017

Primary Completion Date

September 3, 2021

Study Completion Date

September 3, 2021

Conditions

GERDEPS

Interventions

DEVICE

Neobianacid®

Oral administrations of Neobianacid® (30' after meals and on demand)

DRUG

Omeprazole 20mg

Daily administration Omeprazole 20mg (per os, 30' before breakfast).

OTHER

Neobianacid® placebo

Oral administrations of Neobianacid® placebo (30' after meals and on demand)

OTHER

Omeprazole placebo

Daily administration Omeprazole placebo (per os, 30' before breakfast).

Trial Locations (12)

Policlinico San Matteo Pavia Fondazione IRCCS, Pavia

Azienda Ospedaliera Universitaria San Giovanni di Dio e Ruggi d'Aragona, Salerno

Azienda Ospedaliera Santa Maria Goretti, Latina

Ospedale Civile San Salvatore, L’Aquila

Azienda Ospedaliera Perugia, Perugia

Azienda Ospedaliera Sant'Andrea, Rome

Ospedale San Giovanni Addolorata, Rome

Ospedale Sandro Pertini, Rome

Ospedale Sant'Eugenio, Rome

Policlinico Umberto I, Rome

Policlinico Universitario A. Gemelli, Rome

Policlinico Universitario Campus Biomedico di Roma, Rome